Martin Treder
Founder at LTZ Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ulrich Grau | M | 75 | 9 years | |
| Bernhard R. M. Ehmer | M | 69 | 8 years | |
| Robert Li | M | - |
LTZ Therapeutics, Inc.
 LTZ Therapeutics, Inc. BiotechnologyHealth Technology LTZ Therapeutics, Inc. is an American immunotherapy-focused biotech company that develops novel therapies. The company was founded by Jianhui Zhou, Robert Li, and Martin Treder, with Robert Li serving as the CEO since incorporation. | - |
| Jianhui Zhou | M | - |
LTZ Therapeutics, Inc.
LTZ Therapeutics, Inc. BiotechnologyHealth Technology LTZ Therapeutics, Inc. is an American immunotherapy-focused biotech company that develops novel therapies. The company was founded by Jianhui Zhou, Robert Li, and Martin Treder, with Robert Li serving as the CEO since incorporation. | - |
| Mathieu Simon | M | 68 | 6 years | |
| Susanne Hering | F | - | 9 years | |
| Wolfgang Fischer | M | 60 | 7 years | |
| Denise Mueller | F | 55 | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Caroline Y. Stewart | F | - | - | |
| Gregory W. Gin | M | - | - | |
| Irina Staatz-Granzer | M | 64 |
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
| Anne Kerber | M | - | - | |
| Jean Deleage | M | 83 |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | 9 years |
| Michael Wolf | M | - | - | |
| Oscar Kashala | M | - | - | |
| Andrew Curtis | M | - | - | |
| Jöerg Windisch | M | 53 | 1 years | |
| Leila Alland | M | 61 | 1 years | |
| Anca Alexandru | M | - | - | |
| Cassandra Choe-Juliak | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 18 | 90.00% |
| United States | 2 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Martin Treder
- Personal Network
